Drug class
Antiseizure medicine (ASM); high-affinity synaptic vesicle protein 2A (SV2A) ligand
Mechanism of action
The precise mechanism by which brivaracetam exerts its anticonvulsant effect is not known. It binds with high and selective affinity to synaptic vesicle protein 2A (SV2A) in the brain; this binding may contribute to its antiseizure activity and should not be presented as a fully established causal mechanism.
General use cases
- Treatment of partial-onset (focal) seizures in patients aged 1 month and older; may be used as monotherapy or adjunctive therapy according to the specific product label and jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
